Axsome Therapeutics (AXSM) Net Margin (2022 - 2026)
Axsome Therapeutics (AXSM) posted Net Margin of 33.76% for Q1 2026, down 131.08% sequentially from 14.61% in Q4 2025, and up 1516.0% YoY from 2.09% in Q1 2025.
Powered by 
Analysis
Axsome Therapeutics (AXSM) Net Margin (2022 - 2026) Analysis & Trends
Axsome Therapeutics has reported Net Margin for 5 years, with the latest figure at 33.76% in Q1 2026.
- Quarterly Net Margin rose 1516.0% year-over-year to 33.76% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 26.6% (up 6205.0% YoY) and the FY2025 annual result came in at 28.69%, up 4577.0% from the prior year.
- Net Margin eased to 33.76% in Q1 2026 per AXSM's latest filing, from 14.61% in the prior quarter.
- Over five years, Net Margin peaked at 11.88% in Q1 2023 and troughed at 14982.4% in Q4 2024.
- A 5-year average of 1048.22% and a median of 91.09% in 2024 frame the typical range for Net Margin.
- The sharpest annual moves came in 2024 and 2025: Net Margin plunged 1484451 bps in 2024, then jumped 1496779 bps in 2025.
- Over 5 years, Net Margin stood at 251.29% in 2022, then jumped by 45 bps to 137.89% in 2023, then sank by 10765 bps to 14982.4% in 2024, then jumped by 100 bps to 14.61% in 2025, then tumbled by 131 bps to 33.76% in 2026.
- According to Business Quant data, Net Margin over the past three periods registered 33.76%, 14.61%, and 27.62% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.51 Bn | 130.66 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 85.24 Bn | 77.25 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 63.46 Bn | 58.28 Bn | 1.37 Bn | 31.16% |
| 4 | Moderna | 57.89 Bn | 52.75 Bn | 52.00 Mn | -539.31% |
| 5 | Revolution Medicines | 44.02 Bn | 44.02 Bn | - | - |
| 6 | BeOne Medicines | 39.95 Bn | 34.85 Bn | 1.53 Bn | 13.90% |
| 7 | Alnylam Pharmaceuticals | 35.49 Bn | 32.19 Bn | 992.69 Mn | 12.74% |
| 8 | Royalty Pharma | 28.43 Bn | 27.59 Bn | - | 12.09% |
| 9 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.12% |
| 10 | Axsome Therapeutics | 10.72 Bn | 10.40 Bn | 204.81 Mn | -23.50% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -23.50% |
| Mar 31, 2026 | -33.76% |
| Dec 31, 2025 | 4.77% |
| Sep 30, 2025 | -27.62% |
| Jun 30, 2025 | -31.95% |
| Mar 31, 2025 | -48.91% |
| Dec 31, 2024 | -14,982.40% |
| Sep 30, 2024 | -61.67% |
| Jun 30, 2024 | -91.03% |
| Mar 31, 2024 | -91.14% |
| Dec 31, 2023 | -137.89% |
| Sep 30, 2023 | -107.58% |
| Jun 30, 2023 | -143.83% |
| Mar 31, 2023 | -11.88% |
| Dec 31, 2022 | -251.29% |
| Sep 30, 2022 | -266.08% |
| Jun 30, 2022 | -469.82% |